VBL Therapeutics, a clinical-stage biotechnology company committed to the fare of novel treatments for immune-inflammatory diseases and cancer, today announced the reporting of preclinical data in the Journal of Neuroimmunology finding that its lead growth aspirant VB-201 significantly delayed the onset and severity of tentative




if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.write( autoimmune encephalomyelitis (EAE) in mice, the customarily used manifold sclerosis.

More: - The rest...